Product Description
Mechanisms of Action: TLR2 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Opsona
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Preleukemia|Myelodysplastic Syndrome|Renal Transplant|Heart Transplant|Heart Block|Inflammation|Kidney Transplant|Transplantation Unspecified
Phase 1: Parkinson's Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NM-101-01-2022 | P1 |
Unknown status |
Parkinson's Disease |
2024-05-30 |
|
| OPN-305-110 | P2 |
Completed |
Myelodysplastic Syndrome|Preleukemia |
2019-01-10 |
23% |
| OPN-305-106 | P2 |
Completed |
Myelodysplastic Syndrome|Preleukemia |
2018-12-01 |
23% |
| 2012-001455-39 | P2 |
Completed |
Kidney Transplant|Renal Transplant |
2016-06-30 |